Sorrento, Under Shadow Of Chapter 11, Looks To Move BTK Inhibitor Into Phase III

 
• By Alaric DeArment
  
Sorrento announced results from its Phase IIa trial of abivertinib in marginal zone lymphoma • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D